FDA APPROVES VIVITROL FOR ALCOHOL DEPENDENCE
The FDA has approved Vivitrol, the first once-monthly injectable medication to treat alcohol dependence, reported drugmakers Alkermes and Cephalon.
Vivitrol (naltrexone for extended-release injectable suspension) is indicated for alcohol-dependent patients who are able to abstain from drinking in an outpatient setting and not actively drinking at the time treatment begins.
Alcoholism is a prevalent disease that affects nearly 10 percent of the U.S. adult population, with an estimated 100,000 Americans expected to die each year from alcohol-related disease or injury, according to the Agency for Health Care Policy and Research (AHCPR), a branch of the Agency for Healthcare Research and Quality. The annual cost to the nation has been estimated to exceed $166 billion, the agency says.
Vivitrol works by binding to opioid receptors in the brain, which preclinical data suggest leads to the blocking of neurotransmitters linked to alcohol dependence.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May